Edition:
India

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

16.74USD
18 May 2018
Change (% chg)

$0.18 (+1.09%)
Prev Close
$16.56
Open
$16.61
Day's High
$16.90
Day's Low
$16.45
Volume
1,010,467
Avg. Vol
898,462
52-wk High
$17.40
52-wk Low
$7.43

Chart for

About

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $2,478.36
Shares Outstanding(Mil.): 164.57
Dividend: --
Yield (%): --

Financials

  FOLD.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -1.46 -- --
ROI: -24.93 14.84 14.38
ROE: -69.35 16.34 16.07

BRIEF-Amicus Therapeutics Reports Q1 Loss Per Share Of $0.28

* AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES

08 May 2018

BRIEF-Amicus Therapeutics Prices Underwritten Offering Of Common Stock

* AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK

16 Feb 2018

BRIEF-Amicus Therapeutics Announces Public Offering Of Common Stock

* AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

15 Feb 2018

BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat

* U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

12 Feb 2018

BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study

* AMICUS THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE DATA IN POMPE DISEASE PHASE 1/2 STUDY AT 14TH ANNUAL WORLDSYMPOSIUM™

08 Feb 2018

BRIEF-Amicus Launches Galafold For Treatment Of Fabry Disease In Spain

* AMICUS THERAPEUTICS LAUNCHES GALAFOLD™ (MIGALASTAT) FOR TREATMENT OF FABRY DISEASE IN SPAIN Source text for Eikon: Further company coverage:

18 Jan 2018

BRIEF-Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln

* AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE

08 Jan 2018

BRIEF-Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat

* AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

14 Dec 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €66.44 +0.32
Shire PLC (SHP.L) 4,199.00 -19.00
Shire PLC (3159084.L) -- --
Actelion Ltd (ATLN.S) -- --

Earnings vs. Estimates